Systimmune, Inc, A Clinical-Stage Biopharmaceutical Company, Announced That The Us Food And Drug Administration (Fda) Authorized The Company To Proceed With The Planned Clinical Study Of Bl-B01D1 In The Investigational New Drug (Ind) Application On June 30, 2023. This Milestone Paves The Way For Phase 1 Clinical Trials Of Bl-B01D1 In Subjects With Metastatic Or Unresectable Non-Small Cell Lung Cancer (Nsclc) In The United States.The Clearance Of This Ind Application Marks A Significant Milestone For Systimmune As The Company Continues To Advance Its Pipeline Of Novel Therapeutic Candidates Into Clinical Development. Dr. Yi Zhu, Chief Executive Officer Of Systimmune, Commented, "Our Mission At Systimmune Is To Invent Therapies That Offer Meaningful Clinical Benefit To Patients, And The Fda Green Light Of Our Ind Application For Bl-B01D1 Is A Testament To Our Commitment. Together, With All Our Clinical Partners, Trial Treatment Centres, And Global Regulatory Agencies, We Hope To Provide Significant And Global Contributions To The Cancer Treatment Landscape.
